Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prostatype Genomics ABFRA:PGO0 -1.96%23 OCF Yield % is -94.73 as of Aug. 08, 2026. GuruFocus rates FRA:PGO0 with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks worse than 96.24% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Prostatype Genomics AB's OCF Yield % or its related term are showing as below:
FRA:PGO0'
s OCF Yield % Range Over the Past 10 Years
Min: -3274.31 Med: -18.34 Max: -0.75
Current: -94.73
During the past 7 years, the highest OCF Yield % of Prostatype Genomics AB was -0.75%. The lowest was -3274.31%. And the median was -18.34%.
FRA:PGO0's OCF Yield % is ranked worse than 96.24% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.16
vs FRA:PGO0: -94.73
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Prostatype Genomics AB OCF Yield % Related Terms
Prostatype Genomics AB OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PGO0 vs TMO, DHR, IDXX: OCF Yield % Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (FRA:PGO0) has a OCF Yield % of -94.73 as of Aug. 08, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #205 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 96.2%.
Is Prostatype Genomics AB's OCF Yield % too high?
Prostatype Genomics AB's current OCF Yield % is -94.73. Based on the distribution chart, Prostatype Genomics AB ranks #205 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #205 out of 213 companies for OCF Yield %. This places Prostatype Genomics AB in the lower half of its industry. The industry median OCF Yield % is 1.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.16, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current OCF Yield % is -94.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Prostatype Genomics AB (FRA:PGO0) has a current OCF Yield % of -94.73. The current OCF Yield % is -94.73. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Prostatype Genomics AB (FRA:PGO0), the current OCF Yield % is -94.73 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for FRA:PGO0
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PGO0 has been successfully added to your 
